Ailux’s cover photo
Ailux

Ailux

Biotechnology Research

Somerville, Massachusetts 1,715 followers

Lighting the Path to Cures

About us

Ailux is an AI-native biotech company headquartered in Shanghai and currently a wholly-owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery. Established as an independent operation five years ago with its own dedicated team, platforms, and pipeline, Ailux combines proprietary AI biologics platforms with a 30,000 square foot wet lab to discover and engineer next-generation biologics across multiple therapeutic areas. The company’s global team of approximately 150 spans China, the UK, and the US, drawing on the distinct strengths of each geography. Ailux has collaborated with Eli Lilly, Johnson & Johnson, and UCB, and is now advancing its own pipeline with the first programs expected to enter clinical development by 2027.

Website
https://ailuxbio.com/
Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Somerville, Massachusetts
Type
Privately Held
Founded
2021
Specialties
Antibody Discovery, Antibody Engineering, Biologics, AI, and Drug Discovery

Locations

Employees at Ailux

Updates

  • Ailux reposted this

    I am delighted to share that I am joining Ailux as Chief Scientific Officer. My passion has always been translating science into the clinic and ultimately delivering medicines to patients with unmet need. I’m excited to be joining Ailux at such an important stage in its journey, and several aspects of the company particularly stand out to me. First, the strength of the research team in China, combined with a truly geo-optimized model — bringing together the speed and innovation of early discovery in China with deep expertise in disease biology and clinical development in the West. Very few companies are intentionally built from the outset to execute this model well. Second, the company’s pragmatic approach to AI strongly resonates with me. The focus is not on technology for its own sake, but on how AI—when tightly integrated with experimental (“wet lab”) science—can meaningfully improve outcomes, and in some cases enable what would not otherwise be possible. What is particularly compelling is the discipline behind this approach: a clear recognition that AI’s impact is context-dependent, and a commitment to rigorous validation against real experimental data. More broadly, I am inspired by the ambition to build a durable, independent biopharma company—one that advances programs all the way to patients. That long-term orientation, combined with the depth of scientific thinking underpinning the platform, makes this a uniquely exciting moment to join. I would also like to take this opportunity to thank the incredible colleagues at AstraZeneca, where I have spent nearly nine years. It has been a defining chapter of my career. I am deeply grateful for the guidance, collaboration, and friendship across the organization. A special thank you to the senior leaders who supported and trusted my judgment, and to my team and cross-functional partners who helped build a truly industry-leading portfolio. I am confident that what we achieved together will ultimately make a meaningful difference for patients living with serious respiratory and immunology diseases. I look forward to this next chapter.

    View organization page for Ailux

    1,715 followers

    We're excited to welcome Prof. Maria Belvisi to Ailux as our Chief Scientific Officer! Prof. Belvisi joins us from AstraZeneca, where she served as SVP of Research & Development, Respiratory & Immunology, and built one of the most productive early R&D organizations in global pharma. She will lead Ailux's scientific strategy and new program development, and will establish and lead a UK research site to complement Ailux's Shanghai research capabilities. Read more here: https://lnkd.in/eaAyARwQ ailuxbio.com

    • No alternative text description for this image
  • View organization page for Ailux

    1,715 followers

    Endpoints News went behind the scenes with the Ailux leadership team this week. Our CEO Alex Li and newly appointed CSO Maria Belvisi sat down with Andrew Dunn to share our founding story and what it truly means to build a next-generation AI-native global biopharma. Read it here: https://lnkd.in/e3fbFdYg ailuxbio.com

  • View organization page for Ailux

    1,715 followers

    We're excited to welcome Prof. Maria Belvisi to Ailux as our Chief Scientific Officer! Prof. Belvisi joins us from AstraZeneca, where she served as SVP of Research & Development, Respiratory & Immunology, and built one of the most productive early R&D organizations in global pharma. She will lead Ailux's scientific strategy and new program development, and will establish and lead a UK research site to complement Ailux's Shanghai research capabilities. Read more here: https://lnkd.in/eaAyARwQ ailuxbio.com

    • No alternative text description for this image
  • View organization page for Ailux

    1,715 followers

    We’re excited to have been selected for both a Digital Oral Presentation and a Guided Poster at ECCO'26 this week. At the Congress, we will present preclinical data from our 𝗧𝗟𝟭𝗔/𝗜𝗟-𝟮𝟯 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 program for IBD, along with data on a 𝗧𝗟𝟭𝗔 𝗺𝗼𝗻𝗼𝗰𝗹𝗼𝗻𝗮𝗹 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 that exhibits a potential first-in-class mechanism of action and differentiated approach to TL1A blockade. Read the full announcement here: https://lnkd.in/giUszTvW We look forward to engaging with clinicians, researchers, and potential partners in Sweden to discuss how AI-powered, next-generation biologics can raise the efficacy ceiling for patients living with IBD. #ECCO26 #IBD #AntibodyDiscovery #Immunology

  • View organization page for Ailux

    1,715 followers

    On Nov. 5, 2025, we entered into a strategic collaboration with Eli Lilly and Company for bispecific antibody development. This partnership is built upon Ailux's AI-powered bispecific antibody engineering platform. The total deal value is up to $𝟯𝟰𝟱 𝗺𝗶𝗹𝗹𝗶𝗼𝗻, including upfront and near-term payments totaling a 𝗱𝗼𝘂𝗯𝗹𝗲-𝗱𝗶𝗴𝗶𝘁 𝗺𝗶𝗹𝗹𝗶𝗼𝗻-𝗱𝗼𝗹𝗹𝗮𝗿 amount. Lilly may nominate target pairs for bispecific antibody design and may also obtain a license to Ailux's proprietary platform for internal use. Read the in-depth coverage by Darren Incorvaia at Fierce Biotech: https://lnkd.in/gJpXnyz8

  • View organization page for Ailux

    1,715 followers

    We're glad to announce a strategic collaboration with Eli Lilly and Company to advance bispecific antibody development. This collaboration provides Lilly with access to Ailux's AI-powered bispecific antibody engineering platform to deliver novel, efficacious, and developable therapeutic candidates. Ailux will receive upfront and near-term payments totaling a 𝗱𝗼𝘂𝗯𝗹𝗲-𝗱𝗶𝗴𝗶𝘁 𝗺𝗶𝗹𝗹𝗶𝗼𝗻-𝗱𝗼𝗹𝗹𝗮𝗿 𝗮𝗺𝗼𝘂𝗻𝘁, including a platform license option. The total potential value of the deal is up to $𝟯𝟰𝟱 𝗺𝗶𝗹𝗹𝗶𝗼𝗻. We're excited to partner with Lilly and leverage our AI-powered solutions to transform the landscape of biotherapeutics development! Full press release: https://lnkd.in/ejY5apDK

  • View organization page for Ailux

    1,715 followers

    🚀 We're headed to #PEGS2025, the epicenter of innovation in protein and antibody engineering! Join us at 𝟭𝟮:𝟱𝟬𝗣𝗠 on 𝗧𝘂𝗲𝘀𝗱𝗮𝘆, 𝗠𝗮𝘆 𝟭𝟯 for a presentation: 𝗔𝗜-𝗣𝗼𝘄𝗲𝗿𝗲𝗱 𝗜𝗺𝗺𝘂𝗻𝗲 𝗥𝗲𝗽𝗲𝗿𝘁𝗼𝗶𝗿𝗲 𝗠𝗶𝗻𝗶𝗻𝗴 𝗮𝗻𝗱 𝗠𝘂𝗹𝘁𝗶-𝗢𝗯𝗷𝗲𝗰𝘁𝗶𝘃𝗲 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴. This year at PEGS, we want to connect with partners who are looking to develop complex biologics therapeutics with experts in AI. If you're passionate about platform innovation, contact us here: https://lnkd.in/erRCeawv

    • No alternative text description for this image

Affiliated pages

Similar pages

Browse jobs